Anemia: A Potential Source of Bias in Clinical Trials of Angiogenesis Inhibitors: A Hypothesis

Although anemia may cause angiogenesis and neovascularization, especially in ocular situations, neither published nonrandomized clinical trials nor registered have reported the status as inclusion or exclusion criteria their design. Increases circulating levels of erythropoietin vascular endothelial growth factor are proportional to tissue hypoxia, which influenced by hematocrit. Erythropoietin is a potent retinal angiogenic that independent capable stimulating ischemia-induced angiogenesis. We suggest investigating anti-vascular treatment for neovascularization should measure appropriate variables such serum erythropoietin, factor, hemoglobin, hematocrit yield preliminary data future inhibitors. Ignoring status, and/or could create uncertainty subtle statistical bias both systematic reviews aim evaluate efficiency inhibitors several medical including but not limited alterations, rheumatoid arthritis, many types cancer, just mention few. Implications this type be involved other disease situations used medication, different carcinomas well metastases. In hypothesis paper, we match participants its severity avoid game-changing analysis.